313 related articles for article (PubMed ID: 11828718)
1. [Clinical significance of WHO classification and MDS 2000 classification in myelodysplastic syndromes].
Akiba M; Matsuda A; Misumi M; Yagasaki F; Bessho M
Rinsho Ketsueki; 2001 Dec; 42(12):1162-9. PubMed ID: 11828718
[TBL] [Abstract][Full Text] [Related]
2. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
[TBL] [Abstract][Full Text] [Related]
3. [Karyotypic and IPSS grouping of primary myelodysplastic syndromes patients: a comparison between FAB- and WHO-classification].
Yu MH; Liu SH; Shao YQ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):482-5. PubMed ID: 15555265
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
[TBL] [Abstract][Full Text] [Related]
5. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
6. [An analysis of prognostic factors in 80 myelodysplastic syndrome].
Xu XQ; Wang JM; Lu SQ; Chen L; Yang JM; Zhang WP; Song XM; Xu YQ; Gong SL; Hou J; Ni X
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):723-7. PubMed ID: 19176004
[TBL] [Abstract][Full Text] [Related]
7. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
[TBL] [Abstract][Full Text] [Related]
8. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
[TBL] [Abstract][Full Text] [Related]
9. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
11. [Study on prognostic factors in twenty-five patients with myelodysplastic syndrome].
Toyama T; Uno H; Yamashita K; Kubuki Y; Suzuki M; Maeda K; Matsuoka H; Tsubouchi H
Gan To Kagaku Ryoho; 1995 Feb; 22(2):227-32. PubMed ID: 7857097
[TBL] [Abstract][Full Text] [Related]
12. [Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].
Dewulf G; Gouin I; Pautas E; Gaussem P; Chaïbi P; Andreux JP; Siguret V
Ann Biol Clin (Paris); 2004; 62(2):197-202. PubMed ID: 15047472
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of regulatory T cells in patients with myelodysplastic syndrome.
Hamdi W; Ogawara H; Handa H; Tsukamoto N; Nojima Y; Murakami H
Eur J Haematol; 2009 Mar; 82(3):201-7. PubMed ID: 19018862
[TBL] [Abstract][Full Text] [Related]
14. [Myelodysplastic syndrome--classification, prognosis and therapy].
Cermák J; Michalová K; Vítek A
Cas Lek Cesk; 2002 Sep; 141 Suppl():33-7. PubMed ID: 12428420
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes according to FAB and WHO classification. Single center experience.
Haus O; Kotlarek-Haus S; Potoczek S; Czarnecka M; Duszenko E; Makowska I; Mirowska N; Kuliczkowski K
Neoplasma; 2006; 53(2):136-43. PubMed ID: 16575469
[TBL] [Abstract][Full Text] [Related]
16. Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival.
Breccia M; Latagliata R; Carmosino I; Gentilini F; D'Elia GM; Levi A; Natalino F; Frustaci A; De Cuia MR; Alimena G
Acta Haematol; 2007; 117(4):221-5. PubMed ID: 17259693
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
[TBL] [Abstract][Full Text] [Related]
18. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
[TBL] [Abstract][Full Text] [Related]
19. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
[TBL] [Abstract][Full Text] [Related]
20. Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes.
Breccia M; Carmosino I; Biondo F; Mancini M; Russo E; Latagliata R; Alimena G
Leuk Res; 2006 Feb; 30(2):178-82. PubMed ID: 16102825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
